Phase II study of adjuvant imatinib mesylate (IM) in patients after resection of primary gastrointestinal stromal tumor (GIST): Efficacy and safety at one year.


Yalcin S., Buyukberber S., Yilmaz U., Lee P., Srimuninnimit V., Lin P., ...More

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30 identifier

  • Publication Type: Conference Paper / Summary Text
  • Volume: 30
  • City: Illinois
  • Country: United States Of America